- ?? Blog ActionCovid1984.org
- ?? Irish Examiner
- Inverse
- ?? Gript media
- Blake-Lemoine - LaMBDA
- ?? Over Dee Wall
- The Defender News
- ?? BreakingNews.ie
- Dr Vernon Coleman
- Rebel News
- Vaccine Choice Canada NEWS
- SHFT Plan
- The Expose
- ?? Robert Pierzyński PJ
- James Roguskii - Substack
- ?? The Burkean
- Liberty Tactics IM
- stewpeters.com
- Technocracy News
- Interesting Engineering
- ?? Media Hub Ireland
- ?? The Irish Inquiry
- ?? Andy Heasman
- ?? GriptMedia
- ?? WeThePeople.ie
- ?? Action-Covid-1984
- ?? Lets wake up our Capital
- ?? Lets Wake Up Call!!!
- WW Freedom Rallies
- Piers Corbyn
- ?? Tracey OMahony
- ?? The Irish Git
- eIRe is falling
- Peter Madden Channel
- rish Farmers,Food & Family
- Gemma O'Doherty
What's new
What's new
Timetable: Initial (full) marketing authorisation application accelerated assessment timetables - Advanced therapy medicinal product (ATMP)
Timetable: Initial (full) marketing authorisation application accelerated assessment timetables - Advanced therapy medicinal product (ATMP)
18 April 2024
Timetable: Initial (full) marketing authorisation application accelerated assessment timetables
Timetable: Initial (full) marketing authorisation application accelerated assessment timetables
18 April 2024
Timetable accelerated assessment request for initial marketing authorisation applications
Timetable accelerated assessment request for initial marketing authorisation applications
18 April 2024
Human medicines European public assessment report (EPAR): Sitagliptin / Metformin hydrochloride Mylan, sitagliptin hydrochloride monohydrate,metformin hydrochloride, Date of authorisation: 16/02/2022, Revision: 3, Status: Authorised
Human medicines European public assessment report (EPAR): Sitagliptin / Metformin hydrochloride Mylan, sitagliptin hydrochloride monohydrate,metformin hydrochloride, Date of authorisation: 16/02/2022, Revision: 3, Status: Authorised
18 April 2024
Timetable: Companion diagnostic initial consultation - ATMP
Timetable: Companion diagnostic initial consultation - ATMP
18 April 2024
Human medicines European public assessment report (EPAR): Inflectra, infliximab, Date of authorisation: 10/09/2013, Revision: 30, Status: Authorised
Human medicines European public assessment report (EPAR): Inflectra, infliximab, Date of authorisation: 10/09/2013, Revision: 30, Status: Authorised
18 April 2024
Human medicines European public assessment report (EPAR): Lenvima, lenvatinib, Date of authorisation: 28/05/2015, Revision: 21, Status: Authorised
Human medicines European public assessment report (EPAR): Lenvima, lenvatinib, Date of authorisation: 28/05/2015, Revision: 21, Status: Authorised
18 April 2024
Human medicines European public assessment report (EPAR): Cystagon, mercaptamine bitartrate, Date of authorisation: 23/06/1997, Revision: 18, Status: Authorised
Human medicines European public assessment report (EPAR): Cystagon, mercaptamine bitartrate, Date of authorisation: 23/06/1997, Revision: 18, Status: Authorised
18 April 2024